IL3 and neoplasm: After being secreted by activated T cells, monocytes, and/or tumor-associated stromal cells, IL-3 could induce a concomitant increase in the percentage of both Foxp3+ Tregs and IL-2 secreting Th cells in a dose-dependent manner (104, 105).